TG Therapeutics Inc
Suletud
SektorTervishoid
64.4 0.36
Ülevaade
Aktsiahinna muutus
24h
Min
63.94
Max
64.62
Sissetulek | 48M 55M |
|---|---|
Müük | 20M 260M |
P/E Sektori keskmine | 94.597 68.089 |
Aktsiakasum | 0.35 |
Kasumimarginaal | 21.337 |
Töötajad | 399 |
EBITDA | 64M 86M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +18.43% upside |
Turukapital | 525M 9.7B |
|---|---|
Eelmine avamishind | 64.04 |
Eelmine sulgemishind | 64.4 |
TG Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
TG Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
18.43% tõus
12 kuu keskmine prognoos
Keskmine 76.4 USD 18.43%
Kõrge 86 USD
Madal 71 USD
Põhineb 6 Wall Streeti analüütiku instrumendi TG Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.